tradingkey.logo

Eli Lilly and Co

LLY
View Detailed Chart

738.210USD

-50.990-6.46%
Close 04/04, 16:00ETQuotes delayed by 15 min
699.48BMarket Cap
66.05P/E TTM

Eli Lilly and Co

738.210

-50.990-6.46%
Intraday
1m
30m
1h
D
W
M
D

Today

-6.46%

5 Days

-10.13%

1 Month

-20.59%

6 Months

-16.78%

Year to Date

-4.37%

1 Year

-5.86%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 29 analysts
BUY
Current Rating
1017.810
Target Price
37.88%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

151
Total
5
Median
7
Average
Company name
Ratings
Analysts
Eli Lilly and Co
LLY
29
Biogen Inc
BIIB
37
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
BioMarin Pharmaceutical Inc
BMRN
29
1
2
3
...
30

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(10)
Neutral(0)
Buy(0)
Indicators
Sell(4)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-16.460
Sell
RSI(14)
29.179
Sell
STOCH(KDJ)(9,3,3)
9.302
Oversold
ATR(14)
27.004
High Vlolatility
CCI(14)
-263.050
Oversold
Williams %R
97.495
Oversold
TRIX(12,20)
-0.278
Sell
StochRSI(14)
0.000
Sell
Moving Average
Sell(6)
Neutral(0)
Buy(0)
Indicators
Value
Direction
MA5
795.332
Sell
MA10
816.400
Sell
MA20
820.961
Sell
MA50
847.088
Sell
MA100
813.673
Sell
MA200
853.893
Sell

Company

Eli Lilly and Company is a medicine company. The Company discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; and Zepbound. Its oncology products include Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).
Company codeLLY
CompanyEli Lilly and Co
CEOMr. David A. (Dave) Ricks
Websitehttps://www.lilly.com/
tradingkey.logo
tradingkey.logo
Intraday Data provided by Refinitiv and subject to terms of use. Historical and current end-of-day data provided by Refinitiv. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
* References, analysis, and trading strategies are provided by the third-party provider, Trading Central, and the point of view is based on the independent assessment and judgement of the analyst, without considering the investment objectives and financial situation of the investors.
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.